Hypothesis: Simultaneous blockade of ZDHHC7-dependent S-palmitoylation of NLRP3 and downstream IL-6/IL-11 signaling will produce a synergistic reduction of the senescence-associated secretory phenotype (SASP) and restore youthful immune function in older humans.

Mechanistic rationale: ZDHHC7-mediated palmitoylation of NLRP3 at Cys126 promotes its oligomerization and ASC speck formation, driving caspase-1 activation. Active caspase-1 not only cleaves pro-IL-1β to IL-1β but also processes pro-IL-33 into a potent inflammatory isoform that stimulates fibroblasts and epithelial cells to secrete IL-11. Thus, inhibiting ZDHHC7 lowers NLRP3 inflammasome output, decreasing both IL-1β and the IL-33-driven IL-11 axis. IL-1β further induces autocrine IL-6 production via NF-κB, activating STAT3 and reinforcing SASP. IL-6 and IL-11 each activate STAT3 (IL-6) or STAT1/STAT3 (IL-11) pathways in senescent T cells and stromal cells, sustaining mitochondrial ROS production and inhibiting autophagy. Dual targeting therefore attacks the loop at two points: upstream palmitoylation inhibition reduces cytokine generation, while IL-6R and IL-11R blockade prevents residual cytokine signaling, breaking the feed-forward circuit and allowing mitochondria to recover membrane potential and ATP production.

Testable prediction: In a randomized, double-blind, placebo-controlled trial of adults aged 65-80, participants receiving a ZDHHC7 inhibitor (e.g., a selective small-molecule or lipid-nanoparticle-delivered siRNA) plus an IL-6 receptor antagonist (tocilizumab) and an IL-11 receptor antagonist (anti-IL-11 antibody) will show a greater decline in circulating SASP markers (IL-6, IL-11, CRP, GDF-15) and a larger increase in mitochondrial DNA copy number in peripheral blood mononuclear cells after 12 weeks than any monotherapy or placebo. Secondary endpoints will include elevated T-cell receptor excision circles (TRECs) reflecting improved thymic output, reduced frailty index scores, and enhanced response to influenza vaccination.

Falsifiability: If the combination therapy fails to produce a statistically significant greater reduction in SASP factors or improvement in mitochondrial biomarkers compared with the best single agent, the hypothesis of synergistic rejuvenation is refuted. Likewise, absence of increased TRECs or functional immunity would indicate that the proposed upstream-downstream axis does not drive immunosenescence in humans.

Novel insight: This hypothesis integrates lipid-mediated inflammasome activation with cytokine network biology, proposing that targeting the lipid modification step of NLRP3 uncovers a vulnerable node that, when combined with cytokine receptor blockade, collapses the self-reinforcing senescence circuit more effectively than targeting either layer alone.